BriaCell Therapeutics (NASDAQ:BCTX) Trading Up 5.4% – Time to Buy?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares shot up 5.4% during trading on Wednesday . The company traded as high as $0.62 and last traded at $0.60. 623,193 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 1,563,530 shares. The stock had previously closed at $0.57.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Stock Performance

The company has a market capitalization of $26.40 million, a PE ratio of -0.67 and a beta of 1.39. The company’s 50-day moving average is $0.78 and its 200 day moving average is $0.98.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.45. On average, analysts forecast that BriaCell Therapeutics Corp. will post -0.58 EPS for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent quarter. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.